About this visual
A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
Sources & further reading
Study source: TRANSCEND-T2D-2 topline results, Eli Lilly ↗
Study source: ClinicalTrials.gov NCT06260722 ↗
Lilly sponsor-reported topline results; complete peer-reviewed data are pending. Weight and A1c figures use the efficacy estimand. Retatrutide remains investigational. Study averages are not individual predictions.
Brand new Phase 3 head-to-head results show impressive weight loss and A1C reductions with retatrutide compared with semaglutide 2 mg!
Eli Lilly announced new topline results today from TRANSCEND-T2D-2, comparing investigational retatrutide with semaglutide (Ozempic 2 mg) in 1,298 adults with type 2 diabetes.
After 80 weeks, the results showed:
🔹 Mean Weight Loss:
• Retatrutide 9 mg: 19.5% (44.3 lbs)
• Retatrutide 12 mg: 20.9% (47.4 lbs)
• Semaglutide 2 mg: 9.4% (20.9 lbs)
🔹 A1C Reduction:
• Retatrutide 9 mg: 2.2 percentage points
• Retatrutide 12 mg: 2.2 percentage points
• Semaglutide 2 mg: 1.8 percentage points
🔹 Additional Findings:
• Greater improvements in triglycerides, non-HDL cholesterol, and systolic blood pressure were reported with retatrutide.
• Treatment discontinuation due to adverse events was 4.8% and 7.9% with retatrutide 9 mg and 12 mg, compared with 2.7% for semaglutide 2 mg.
• Gastrointestinal adverse events were common across treatment groups, and dysesthesia was reported more frequently with retatrutide.
These results are encouraging because achieving substantial weight loss is often more challenging in patients with type 2 diabetes.
This also marks the first Phase 3 trial directly comparing retatrutide with another incretin-based medication, providing head-to-head evidence against an established treatment.
Retatrutide remains investigational, and complete published data are still pending.
Another important study to watch is the ongoing TRIUMPH-5 trial comparing retatrutide directly with tirzepatide.
It's exciting to see continued progress in obesity and diabetes pharmacotherapy, with more treatment options on the horizon.
I've put together an infographic highlighting the key results from today's announcement.
📚 Source: Eli Lilly, October 28, 2026. TRANSCEND-T2D-2 (NCT06260722). Weight and A1C results reflect the efficacy estimand.
#obesitymedicine #retatrutide #glp1 #type2diabetes